Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a “Double Down” signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same “Total Conviction” signal is flashing for a company 1\/100th the size of Nvidia. Continue \u00bb<\/a> <\/p>\n The company is already seeing some encouraging results. For example, Pfizer raised its 2026 revenue guidance<\/a> following its second-quarter results, citing stronger-than-expected performance of its non-COVID portfolio. The company has also continued to pursue opportunities in oncology, vaccines, and obesity. <\/p>\n And there are signs that the underlying business is improving. In its latest quarter, Pfizer said revenue from its launched and acquired products grew 18%. That matters because the long-term dividend story depends on Pfizer replacing the revenue it’s losing from older products with newer medicines. <\/p>\n For income investors, the biggest attraction is still the dividend. Pfizer maintained its quarterly payout at $0.43 per share in 2026 and has committed to maintaining and eventually growing it. Its annual dividend yield is currently about 6%, which is one of the biggest reasons the stock stands out among large pharmaceutical companies. The stock offers investors a high yield while the company works through the post-COVID reset and prepares for upcoming patent expirations. <\/p>\n While Pfizer is rebuilding its business after COVID, another company is building a new portfolio that could become its next growth engine. <\/p>\n Bristol Myers Squibb pairs a high yield with a growing next-gen portfolio <\/p>\n Bristol Myers Squibb, on the other hand, offers another compelling high-yield opportunity. The company has been working to shift its business away from legacy products and toward a newer generation of medicines. And the encouraging part is that Bristol Myers is already seeing its new portfolio contribute meaningfully to results. <\/p>\n Story Continues <\/p>\n Its latest quarter showed continued strength across products, including Reblozyl and Breyanzi, which treat blood-related conditions, helping the company raise its full-year outlook. That transition is becoming more important. Rather than simply relying on old blockbusters, the company is building a broader portfolio across oncology, hematology, and cardiovascular disease. <\/p>\n Meanwhile, Bristol Myers is also replenishing its pipeline through partnerships and acquisitions. It announced a collaboration with Hengrui Pharma covering 13 programs, providing another potential source of future medicines. <\/p>\n There have also been notable pipeline developments. The FDA granted accelerated approval to Zenbexus, the company’s first CELMoD therapy, a type of oral cancer medication, giving the company another potential growth product. <\/p>\n At the same time, Bristol Myers continues to return cash to shareholders. The company raised its dividend for the 17th consecutive year in late 2025 and has maintained the $0.63 quarterly payout through 2026. As a result, the stock offers an annual dividend yield of about 4%. <\/p>\n As both companies invest in the next phase of growth, the question is whether they can maintain their high dividend yields. <\/p>\n Why these two high-yield healthcare stocks stand out <\/p>\n Pfizer and Bristol Myers Squibb offer something income investors don’t often get from large pharmaceutical companies: high dividend yields backed by established businesses and next-generation portfolios. <\/p>\n Both companies generate strong cash flow from widely used medicines, while investing in newer products that could support future revenue growth. That means the decision for investors comes down to risk tolerance. <\/p>\n Pfizer suits investors willing to accept more uncertainty in exchange for the higher yield and a bigger potential payoff if its post-COVID rebuild succeeds, while Bristol Myers Squibb fits those who want a steadier grower, backed by 17 straight years of dividend increases and a next-gen portfolio that’s already gaining traction. <\/p>\n Should you buy stock in Bristol Myers Squibb right now? <\/p>\n Before you buy stock in Bristol Myers Squibb, consider this: <\/p>\n The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks<\/a> for investors to buy now\u2026 and Bristol Myers Squibb wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. <\/p>\n Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $373,352!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,406,241!* <\/p>\n Now, it’s worth noting Stock Advisor’s total average return is 933% \u2014 a market-crushing outperformance compared to 212% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors. <\/p>\n See the 10 stocks \u00bb<\/a> <\/p>\n *Stock Advisor returns as of September 29, 2026. <\/p>\n Rick Orford<\/a> has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bristol Myers Squibb and Pfizer. The Motley Fool has a disclosure policy<\/a>. <\/p>\n<\/a> Image source: Getty Images. <\/p>\n